Castleman's disease-a two compartment model of HHV8 infection

Nature Reviews Clinical Oncology

Volumn 7, Issue 9, 2010, Pages 533-543

  Schulte, Klaus Martin ^a   Talat, Nadia ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BORTEZOMIB; CD19 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LATENCY ASSOCIATED NUCLEAR ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PREDNISONE; RITUXIMAB; STAT PROTEIN; THALIDOMIDE; TOCILIZUMAB; TRANSCRIPTION FACTOR PAX5; VALGANCICLOVIR; VINBLASTINE; VINCRISTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIGEN EXPRESSION; B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD SMEAR; BONE MARROW SUPPRESSION; CARCINOGENESIS; CELL POPULATION; CELL PROLIFERATION; CHRONIC DISEASE; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; EPSTEIN BARR VIRUS; FOLLICULAR DENDRITIC CELL SARCOMA; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPH VESSEL; LYMPHADENOPATHY; NEUTROPHIL CHEMOTAXIS; NONHODGKIN LYMPHOMA; PARANEOPLASTIC PEMPHIGUS; PLASMA CELL; POEMS SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; STAGING; STEM CELL; SYMPTOMATOLOGY; TERATOGENICITY; VASCULAR ENDOTHELIUM; VIRUS INFECTION; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; B-LYMPHOCYTES; DISEASE PROGRESSION; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; LYMPH NODES; VIRUS REPLICATION;

EID: 77956262040     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.103     Document Type: Review

References (119)

1. Castleman, B. & Towne, V. W. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N. Engl. J. Med. 251, 396-400 (1954).
2. Castleman, B., Iverson, L. & Menendez, V. P. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9, 822-830 (1956).
3. Keller, A. R., Hochholzer, L. & Castleman, B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29, 670-683 (1972).
4. Dispenzieri, A. Castleman disease. Cancer Treat. Res. 142, 293-330 (2008).
5. Mylona, E. E. et al. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev. 10, 25-35 (2008).
6. Casper, C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br. J. Haematol. 129, 3-17 (2005).
7. Dham, A. & Peterson, B. A. Castleman disease. Curr. Opin. Hematol. 14, 354-359 (2007).
8. Stebbing, J. et al. HIV-associated multicentric Castleman's disease. Am. J. Hematol. 83, 498-503 (2008).
9. Kessler, E. Multicentric giant lymph node hyperplasia. A report of seven cases. Cancer 56, 2446-2451 (1985).
10. Oksenhendler, E. HIV-associated multicentric Castleman disease. Curr. Opin. HIV AIDS 4, 16-21 (2009).
11. Cronin, D. M. & warnke, R. A. Castleman disease: an update on classification and the spectrum of associated lesions. Adv. Anat. Pathol. 16, 236-246 (2009).
12. Hengge, U. R. et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect. Dis. 2, 344-352 (2002).
13. Mallik, M. K., Kapila, K., Das, D. K., Haji, B. E. & Anim, J. T. Cytomorphology of hyaline-vascular Castleman's disease: a diagnostic challenge. Cytopathology 18, 168-174 (2007).
14. Zettergren, L. Probably neoplastic proliferation of lymphoid tissue (follicular lympho-reticuloma). Reports of four cases with a survey of literature. Acta Pathol. Microbiol. Scand. 51, 113-126 (1961).
15. Harrison, E. G. Jr & Bernatz, P. E. Angiofollicular mediastinal lymph-node hyperplasia resembling thymoma. Arch. Pathol. 75, 284-292 (1963).
16. Tung, K. S. & McCormack, L. J. Angiomatous lymphoid hamartoma. Report of five cases with a review of the literature. Cancer 20, 525-536 (1967).
17. Festen, C., Flendrig, J. A. & Schillings, P. H. [Giant lymphomas]. Ned. Tijdschr. Geneeskd 113, 1918-1919 (1969).
18. Abell, M. R. Lymphnodal hamartoma versus thymic choristoma of pulmonary hilum. AMA Arch. Pathol. 64, 584-588 (1957).
19. Al-Maghrabi, J., Kamel-Reid, S. & Bailey, D. Immunoglobulin and T-cell receptor gene rearrangement in Castleman's disease: molecular genetic analysis. Histopathology 48, 233-238 (2006).
20. Radaszkiewicz, T., Hansmann, M. L. & Lennert, K. Monoclonality and polyclonality of plasma cells in Castleman's disease of the plasma cell variant. Histopathology 14, 11-24 (1989).
21. Nguyen, D. T. et al. Castleman's disease. Differences in follicular dendritic network in the hyaline vascular and plasma cell variants. Histopathology 24, 437-443 (1994).
22. Naresh, K. N., Rice, A. J. & Bower, M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am. J. Surg. Pathol. 32, 1006-1012 (2008).
23. Dupin, N. et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95, 1406-1412 (2000).
24. Oksenhendler, E. et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 96, 2069-2073 (2000).
25. Marcelin, A. G. et al. Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease. J. Infect. Dis. 196, 1163-1166 (2007).
26. Du, M. Q., Bacon, C. M. & Isaacson, P. G. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J. Clin. Pathol. 60, 1350-1357 (2007).
27. Ascoli, V. et al. Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. J. Pathol. 193, 200-209 (2001)
28. westmoreland, S. V. & Mansfield, K. G. Comparative pathobiology of Kaposi sarcoma-associated herpesvirus and related primate rhadinoviruses. Comp. Med. 58, 31-42 (2008).
29. Hayashi, M. et al. Kaposi's sarcoma-associated herpesvirus infection in the lung in multicentric Castleman's disease. Intern. Med. 38, 279-282 (1999).
30. Komatsu, T., Barbera, A. J., Ballestas, M. E. & Kaye, K. M. The Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen. Viral Immunol. 14, 311-317 (2001).
31. Ablashi, D. V., Chatlynne, L. G., whitman, J. E. Jr & Cesarman, E. Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin. Microbiol. Rev. 15, 439-464 (2002).
32. Chang, Y. et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266, 1865-1869 (1994).
33. Pyakurel, P. et al. Lymphatic and vascular origin of Kaposi's sarcoma spindle cells during tumor development. Int. J. Cancer 119, 1262-1267 (2006).
34. Cesarman, E., Chang, Y., Moore, P. S., Said, J. W. & Knowles, D. M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332, 1186-1191 (1995).
35. Horenstein, M. G. et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood 90, 1186-1191 (1997).
36. Moore, P. S. & Chang, Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N. Engl. J. Med. 332, 1181-1185 (1995).
37. Neipel, F. et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J. Virol. 71, 839-842 (1997).
38. Nicholas, J. et al. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat. Med. 3, 287-292 (1997).
39. Brousset, P., Cesarman, E., Meggetto, F., Lamant, L. & Delsol, G. Colocalization of the viral interleukin-6 with latent nuclear antigen-1 of human herpesvirus-8 in endothelial spindle cells of Kaposi's sarcoma and lymphoid cells of multicentric Castleman's disease. Hum. Pathol. 32, 95-100 (2001).
40. Parravicini, C. et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am. J. Pathol. 151, 1517-1522 (1997).
41. Abe, Y. et al. Distinct expression of Kaposi's sarcoma-associated herpesvirus-encoded proteins in Kaposi's sarcoma and multicentric Castleman's disease. Pathol. Int. 56, 617-624 (2006).
42. Foss, H. D. et al. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J. Pathol. 183, 44-50 (1997).
43. Nishimoto, N. & Kishimoto, T. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2, 619-626 (2006).
44. Heinrich, P. C. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1-20 (2003).
45. Nishimoto, N. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959-3964 (2008).
46. Yoshizaki, K. et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74, 1360-1367 (1989).
47. Leger-Ravet, M. B. et al. Interleukin-6 gene expression in Castleman's disease. Blood 78, 2923-2930 (1991).
48. Beck, J. T. et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N. Engl. J. Med. 330, 602-605 (1994).
49. Nishimoto, N. et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95, 56-61 (2000).
50. Aoki, Y. et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93, 4034-4043 (1999).
51. Mori, Y. et al. Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. J. Med. Virol. 61, 332-335 (2000).
52. Hu, F. & Nicholas, J. Signal transduction by human herpesvirus 8 viral interleukin-6 (vIL-6) is modulated by the nonsignaling gp80 subunit of the IL-6 receptor complex and is distinct from signaling induced by human IL-6. J. Virol. 80, 10874-10878 (2006).
53. Hardy, R. R. & Hayakawa, K. B cell development pathways. Annu. Rev. Immunol. 19, 595-621 (2001).
54. MacLennan, I. C. Germinal centers. Annu. Rev. Immunol. 12, 117-139 (1994).
55. Frater, J. L. & Hsi, E. D. Properties of the mantle cell and mantle cell lymphoma. Curr. Opin. Hematol. 9, 56-62 (2002).
56. Dono, M. et al. The human marginal zone B cell. Ann. N. Y. Acad. Sci. 987, 117-124 (2003).
57. Kikuta, H. et al. Tropism of human herpesvirus 8 for peripheral blood lymphocytes in patients with Castleman's disease. Br. J. Haematol. 99, 790-793 (1997).
58. Du, M. Q. et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97, 2130-2136 (2001).
59. Fakhari, F. D. et al. The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J. Clin. Invest. 116, 735-742 (2006).
60. Wong, S. W. et al. Induction of B cell hyperplasia in simian immunodeficiency virus-infected rhesus macaques with the simian homologue of Kaposi's sarcoma-associated herpesvirus. J. Exp. Med. 190, 827-840 (1999).
61. Estep, R. D., Powers, M. F., Yen, B. K., Li, H. & wong, S. W. Construction of an infectious rhesus rhadinovirus bacterial artificial chromosome for the analysis of Kaposi's sarcoma-associated herpesvirus-related disease development. J. Virol. 81, 2957-2969 (2007).
62. O'Connor, C. M. & Kedes, D. H. Rhesus monkey rhadinovirus: a model for the study of KSHV. Curr. Top. Microbiol. Immunol. 312, 43-69 (2007).
63. Bouvresse, S. et al. The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient. AIDS 21, 1492-1494 (2007).
64. Guihot, A. et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells. Blood 111, 1387-1395 (2008).
65. Romani, B., Engelbrecht, S. & Glashoff, R. H. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J. Gen. Virol. 91, 1-12 (2009).
66. Zhou, L. P. et al. Imaging findings of Castleman disease of the abdomen and pelvis. Abdom. Imaging 33, 482-488 (2008).
67. Meador, T. L. & McLarney, J. K. CT features of Castleman disease of the abdomen and pelvis. AJR Am. J. Roentgenol. 175, 115-118 (2000).
68. Ferrozzi, F. et al. Focal Castleman disease of the lung: MRI findings. Clin. Imaging 25, 400-402 (2001).
69. Yamashita, Y. et al. Radiological presentations of Castleman's disease. Comput. Med. Imaging Graph. 17, 107-117 (1993).
70. Guihot, A. et al. Pulmonary manifestations of multicentric Castleman's disease in HIV infection: a clinical, biological and radiological study. Eur. Respir. J. 26, 118-125 (2005).
71. Enomoto, K. et al. Unicentric and multicentric Castleman's disease. Br. J. Radiol. 80, e24-e26 (2007).
72. Halac, M. et al. PET/CT findings in a multicentric form of Castleman's disease. Hell. J. Nucl. Med. 10, 172-174 (2007).
73. Guihot, A. et al. Thoracic radiographic and CT findings of multicentric Castleman disease in HIV-infected patients. J. Thorac. Imaging 22, 207-211 (2007).
74. Dhasmana, D. J., Dheda, K., Ravn, P., wilkinson, R. J. & Meintje, G. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 68, 191-208 (2008).
75. Zietz, C. Bogner, J. R., Goebel, F. D. & Löhrs, U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N. Engl. J. Med. 340, 1923-1924 (1999).
76. Bacon, C. M. et al. Pathology of bone marrow in human herpes virus-8 (HHV8)-associated multicentric Castleman disease. Br. J. Haematol. 127, 585-591 (2004).
77. Oksenhendler, E. et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99, 2331-2336 (2002).
78. Isaacson, P., Campo, G. E. & Harris, N. Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, Eds C. E. Swerdlow et al., 258-259, (wHO, Lyon 2008).
79. Deloose, S. T. et al. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia 19, 851-855 (2005).
80. Bryant, R. J., Banks, P. M. & O'Malley, D. P. Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. Histopathology 48, 505-515 (2006).
81. Maheswaran, P. R., Ramsay, A. D., Norton, A. J. & Roche, W. R. Hodgkin's disease presenting with the histological features of Castleman's disease. Histopathology 18, 249-253 (1991).
82. Saletti, P. et al. Hodgkin's and Castleman's disease in a patient with systemic mastocytosis. Ann. Hematol. 78, 97-100 (1999).
83. Zanetto, U., Pagani, F. P. & Pérez, C. Interfollicular Hodgkin's lymphoma and Castleman's disease. Histopathology 48, 317-319 (2006).
84. Frank, D. K., Charney, D. & Kashani, A. Plasma cell variant of Castleman's disease occurring concurrently with Hodgkin's disease in the neck. Head Neck 23, 166-169 (2001).
85. Jegalian, A. G., Facchetti, F. & Jaffe, E. S. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv. Anat. Pathol. 16, 392-404 (2009).
86. Pellet, C. & Lebbe, C. Kaposi's disease and HHV8: a new model of virus-induced tumorigenesis [French]. Pathol. Biol. (Paris) 48, 529-532 (2000).
87. Zarate-Osorno, A., Medeiros, L. J., Danon, A. D. & Neiman, R. S. Hodgkin's disease with coexistent Castleman-like histologic features. A report of three cases. Arch. Pathol. Lab. Med. 118, 270-274 (1994).
88. Nikolskaia, O. V., Nousari, C. H. & Anhalt, G. J. Paraneoplastic pemphigus in association with Castleman's disease. Br. J. Dermatol. 149, 1143-1151 (2003).
89. Dispenzieri, A. POEMS syndrome. Blood Rev. 21, 285-299 (2007).
90. 18F-FDG PET/CT in the evaluation of POEMS syndrome. Eur. J. Radiol. doi:10.1016/j.ejrad.2009.06.004.
91. Belec, L. et al. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Blood 93, 3643-3653 (1999).
92. Ganti, A. K., Pipinos, I., Culcea, E., Armitage, J. O. & Tarantolo, S. Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. Am. J. Hematol. 79, 206-210 (2005).
93. Obermoser, G., Larcher, C., Sheldon, J. A., Sepp, N. & Zelger, B. Absence of human herpesvirus-8 in glomeruloid haemangiomas associated with POEMS syndrome and Castleman's disease. Br. J. Dermatol. 148, 1276-1278 (2003).
94. Cokelaere, K., Debiec-Rychter, M., De wolf-Peeters, C., Hagemeijer, A. & Sciot, R. Hyaline vascular Castleman's disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis. Am. J. Surg. Pathol. 26, 662-669 (2002).
95. Pauwels, P. et al. A chromosomal abnormality in hyaline vascular Castleman's disease: evidence for clonal proliferation of dysplastic stromal cells. Am. J. Surg. Pathol. 24, 882-888 (2000).
96. Chan, J. K., Tsang, W. Y. & Ng, C. S. Follicular dendritic cell tumor and vascular neoplasm complicating hyaline-vascular Castleman's disease. Am. J. Surg. Pathol. 18, 517-525 (1994).
97. Chan, A. C. et al. Development of follicular dendritic cell sarcoma in hyaline-vascular Castleman's disease of the nasopharynx: tracing its evolution by sequential biopsies. Histopathology 38, 510-518 (2001).
98. Kazakov, D. V., Morrisson, C., Plaza, J. A., Michal, M. & Suster, S. Sarcoma arising in hyaline-vascular castleman disease of skin and subcutis. Am. J. Dermatopathol. 27, 327-332 (2005).
99. Nayler, S. J., Taylor, L. & Cooper, K. HHV-8 is not associated with follicular dendritic cell tumours. Mol. Pathol. 51, 168-170 (1998).
100. Marzano, A. V. et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma and Castleman disease. Br. J. Dermatol. 153, 214-215 (2005).
101. Hsieh, M. L., Quint, L. E., Faust, J. M. & Turner, J. E. Enhancing mediastinal mass at MR: Castleman disease. Magn. Reson. Imaging 11, 599-601 (1993).
102. Mallik, A. A., Katchy, K. C. & Clotan, N. Solitary intracranial Castleman's disease, plasma cell variant: a case report. Med. Princ. Pract. 16, 226-229 (2007).
103. Gaba, A. R., Stein, R. S., Sweet, D. L. & Variakojis, D. Multicentric giant lymph node hyperplasia. Am. J. Clin. Pathol. 69, 86-90 (1978).
104. Casper, C. et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J. Infect. Dis. 198, 23-30 (2008).
105. Matsuyama, M. et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern. Med. 46, 771-774 (2007).
106. Starkey, C. R., Joste, N. E. & Lee, F. C. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am. J. Hematol. 81, 303-304 (2006).
107. Lee, F. C. & Merchant, S. H. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am. J. Hematol. 73, 48-53 (2003).
108. Scott, D., Cabral, L. & Harrington, W. J. Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am. J. Hematol. 66, 148-150 (2001).
109. Bower, M. et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann. Intern. Med. 147, 836-839 (2007).
110. Gérard, L. et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J. Clin. Oncol. 25, 3350-3356 (2007).
111. Buchler, T. et al. Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman's disease with multiorgan failure: report of two cases. AIDS 22, 1685-1687 (2008).
112. Marcelin, A. G. et al. Rituximab therapy for HIV-associated Castleman disease. Blood 102, 2786-2788 (2003).
113. Bestawros, A., Michel, R., Séguin, C. & Routy, J. P. Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series. Am. J. Hematol. 83, 508-511 (2008).
114. Kotb, R. et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur. J. Haematol. 76, 269-271 (2006).
115. Tedder, T. F. CD19: a promising B cell target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 572-577 (2009).
116. Therapontos, C., Erskine, L., Gardner, E. R., Figg, W. D. & Vargesson, N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc. Natl Acad. Sci. USA 106, 8573-8578 (2009)
117. Li, W. w., Hutnik, M. & Gehr, G. Antiangiogenesis in haematological malignancies. Br. J. Haematol. 143, 622-631 (2008).
118. Stary, G. et al. Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide. AIDS 22, 1232-1234 (2008).
119. Hess, G., wagner, V., Kreft, A., Heussel, C. P. & Huber, C. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br. J. Haematol. 134, 544-545 (2006).